Spironolactone Starts Out On ‘Unusual But Not Unprecedented’ Regulatory Path, Thanks To US FDA Reviewers

 
• By Bridget Silverman
upside down house
No sponsor, no application, no problem. • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers